IQVIA debuts research platform to de-ID links between genomic and clinical data

lab
E360 Genomics replaces sensitive identifying data with symbols that represent critical information, while maintaining links between genomic data and clinical outcomes. (Pixabay)

IQVIA has launched a new de-identification platform aimed at real-world genomic research and protecting patient privacy.

The company is pitching its new E360 Genomics offering as a scalable genotypic-phenotypic database that assists researchers working with various genomic and clinical outcome data sets.

The platform allows life science customers to aggregate data to conduct various research projects, including association studies of genomics and observable traits, as well as comparative safety and efficacy trials. It can also securely track burden-of-illness and perform discovery analytics using de-identified data, according to the company.

Training Course

BioBasics: Biotech For The Non-Scientist

BioBasics: Biotech for the Non-Scientist is a two-day course for those who want to better understand the science driving the industry. The course starts with basic scientific concepts and quickly delves into the causes of genetic and infectious disease and the therapeutic strategies used to mitigate disease. The latest innovations in immunotherapies, gene therapy, checkpoint inhibitors, CAR-T and more are explained.

RELATED: QuintilesIMS no more. Say hello to IQVIA

E360 Genomics replaces sensitive data with symbols that represent critical information, without identifying the patient. By removing identifying and phenotypic information from the patient data—while maintaining links between genomic data and clinical outcomes—IQVIA says it can provide more flexible and less expensive approaches to drug discovery and development work.

RELATED: IQVIA and Genomics England to launch real-world research platform as the U.K. looks to boost cancer diagnostics

Late last year, IQVIA began collaborating with Genomics England on a platform connecting clinical results with de-identified genomics data, to help generate evidence for drug research and personalized medicine. It works alongside a new long-term cancer strategy for the NHS, focused on improving early diagnoses.

The project employs IQVIA’s broader E360 platform to help researchers create custom data sets linking clinical and genomic information, and analyze the relationship between genes and observable traits—beginning with patients with rare diseases and their families, as well as those with common cancers.

Suggested Articles

The Chan Zuckerberg Initiative is awarding $17 million for advances in digital microscopy to allow researchers to view the subtleties of disease.

The drug failed to clearly outperform a generic used as a control, leaving room to doubt whether vibegron poses a big threat to Astellas’ Myrbetriq.

The level of interest in gene therapies has been laid bare by a report on Biogen’s pursuit of Nightstar Therapeutics.